Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Outlook on the Epinephrine Autoinjector Global Market to 2028 - Development of Automatic Injection Devices to Further Create Growth Opportunities


DUBLIN, Sept. 26, 2022 /PRNewswire/ -- The "Epinephrine Autoinjector Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The report on the global epinephrine autoinjector market provides qualitative and quantitative analysis for the period from 2022 to 2028. The report predicts the global epinephrine autoinjector market to grow with a CAGR of nearly 8% over the forecast period from 2022-2028. The study on epinephrine autoinjector market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2022 to 2028.

The report on epinephrine autoinjector market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global epinephrine autoinjector market over the period of 2022 to 2028. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global epinephrine autoinjector market over the period of 2022 to 2028. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

2) Restraints

3) Opportunities

What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the epinephrine autoinjector market.
2. Complete coverage of all the segments in the epinephrine autoinjector market to analyze the trends, developments in the global market and forecast of market size up to 2028.
3. Comprehensive analysis of the companies operating in the global epinephrine autoinjector market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Global Epinephrine Autoinjector Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Epinephrine Autoinjector Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Dosage
3.5.2. Growth Matrix Analysis by End-User
3.5.3. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Epinephrine Autoinjector Market

4. Epinephrine Autoinjector Market Macro Indicator Analysis

5. Global Epinephrine Autoinjector Market by Dosage
5.1. 0.15 Mg Epinephrine Autoinjector
5.2. 0.3 Mg Epinephrine Autoinjector
5.3. 0.5 Mg Epinephrine Autoinjector

6. Global Epinephrine Autoinjector Market by End-User
6.1. Hospital
6.2. Clinics
6.3. Individual

7. Global Epinephrine Autoinjector Market by Region 2022-2028
7.1. North America
7.1.1. North America Epinephrine Autoinjector Market by Dosage
7.1.2. North America Epinephrine Autoinjector Market by End-User
7.1.3. North America Epinephrine Autoinjector Market by Country
7.2. Europe
7.2.1. Europe Epinephrine Autoinjector Market by Dosage
7.2.2. Europe Epinephrine Autoinjector Market by End-User
7.2.3. Europe Epinephrine Autoinjector Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Epinephrine Autoinjector Market by Dosage
7.3.2. Asia-Pacific Epinephrine Autoinjector Market by End-User
7.3.3. Asia-Pacific Epinephrine Autoinjector Market by Country
7.4. RoW
7.4.1. RoW Epinephrine Autoinjector Market by Dosage
7.4.2. RoW Epinephrine Autoinjector Market by End-User
7.4.3. RoW Epinephrine Autoinjector Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Epinephrine Autoinjector Market
8.2. Companies Profiled
8.2.1. Pfizer Inc.
8.2.2. Mylan Inc.
8.2.3. ALK Abello
8.2.4. Sanofi SA
8.2.5. Lincoln Medical Ltd
8.2.6. Teva Pharmaceuticals Ltd
8.2.7. Antares Pharma Inc.
8.2.8. Hospira Inc.
8.2.9. Impax Laboratories, Inc.
8.2.10. Bausch & Lomb Incorporated

For more information about this report visit https://www.researchandmarkets.com/r/u4vbbe

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 18:50
In response to the unprecedented challenges that Latin America has faced during various health crises such as AH1N1, Zika, COVID-19, and Dengue, a prominent group of former health ministers and public health academics from the region has published in...

at 18:00
Simply Better Brands Corp. ("SBBC" or the "Company") announces that, further to the Company's news release dated January 25, 2023, and in connection with the Branding Earnout Agreement dated January 25, 2023, the Company has issued 89,966 common...

at 16:35
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Chegg, Inc. . Chegg is a publicly traded educational technology...

at 16:30
Today, the Biden-Harris Administration released a final rule under Section 1557, the core nondiscrimination provision of the Affordable Care Act. This groundbreaking rule marks a critical step in protecting access to health care and coverage for...

at 16:30
Farmmi, Inc. ("Farmmi" or the "Company") , an agriculture products supplier in China, today announced that on April 22, 2024, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is currently not in...

at 16:20
AMC Entertainment Holdings, Inc. (the "Company," or "AMC"), today released preliminary results for the first quarter ended March 31, 2024. The preliminary results are unaudited, subject to completion of the Company's financial reporting processes,...



News published on and distributed by: